PLC Systems To Present At OneMedForum In New York City

MILFORD, Mass., July 9, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF) today announced that it will participate in the OneMedForum NY 2012 investor conference at the Metropolitan Club in New York City. PLC is scheduled to present on Thursday, July 12, 2012 at 9:20 am local time in the Morton Room. Presenting for the company will be Mark R. Tauscher, President and CEO.

The presentation will be streamed live and accessible at the time by visiting the OneMedForum website (www.onemedplace.com, following links for the OneMedForum NY 2012). After the presentation, a webcast replay will be available at PLC's website (www.plcmed.com) by accessing the link on the investor relations page. The webcast will be archived on the company's website for 30 days following completion of the event.

About PLC Systems

PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2011, a copy of which is on file with the SEC.